Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tango Therapeutics ( (TNGX) ) has shared an announcement.
On January 2, 2026, Tango Therapeutics, Inc. expanded its Board of Directors from seven to eight members and appointed Sung H. Lee as an independent Class I director, with a term running until the 2028 annual meeting of stockholders. Lee, a seasoned finance executive with more than two decades of leadership experience at biopharmaceutical and technology firms including Cytokinetics, Vir Biotechnology, MorphoSys, Sangamo Therapeutics and Gilead Sciences, received a standard non-employee director compensation package comprising stock options for 60,000 shares, 10,000 restricted stock units vesting over three years, and a $40,000 annual cash retainer, and is expected to enter into the company’s customary director indemnification agreement. Tango’s leadership highlighted that Lee’s background in corporate strategy, investor relations and finance is expected to support the company as it advances its lead cancer program, vopimetostat, into registrational studies and continues to evolve its organization for late-stage clinical development, underscoring a strategic strengthening of its governance and financial oversight as it approaches critical milestones in its pipeline.
The most recent analyst rating on (TNGX) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.
Spark’s Take on TNGX Stock
According to Spark, TipRanks’ AI Analyst, TNGX is a Neutral.
Tango Therapeutics’ overall stock score is driven by strong technical indicators and positive corporate events, which offset the financial performance challenges. The recent capital raise significantly enhances its financial stability and growth potential, while technical trends suggest a favorable market sentiment. However, ongoing profitability and cash flow issues remain a concern.
To see Spark’s full report on TNGX stock, click here.
More about Tango Therapeutics
Tango Therapeutics, Inc. is a Boston-based, clinical-stage biotechnology company listed on Nasdaq that focuses on discovering and developing next-generation precision cancer medicines. The company is advancing a pipeline that includes its lead program, vopimetostat, and is building capabilities to support late-stage clinical development activities in oncology.
Average Trading Volume: 3,230,050
Technical Sentiment Signal: Buy
Current Market Cap: $1.2B
See more data about TNGX stock on TipRanks’ Stock Analysis page.